European Veterinary Vaccines Market Projected to Reach $5.61 Billion

A regulatory and market analysis released by Research and Markets projects the Europe Veterinary Vaccines Market to grow from $4.08 billion to $5.61 billion by 2031, reflecting a 6.6% compound annual growth rate (CAGR). The expansion is driven by strict EU regulatory frameworks limiting agricultural antimicrobial usage, forcing livestock producers toward preventive immunotherapeutics.

Regulatory & Technology Drivers

• Antimicrobial Resistance (AMR) Compliance: Legislative enforcement under Regulation (EU) 2019/6 has mandated stricter monitoring of prophylactic antibiotic use in food-producing animals, positioning vaccines as an essential biosecurity tool.

• Technological Shifts: While live attenuated vaccines maintain a substantial market share (~41.5%), research investment is rapidly shifting toward recombinant, vector-based, and RNA-particle platforms targeting avian influenza, bovine respiratory disease, and swine fever.

• Competitive Landscape: Market consolidation remains concentrated among global originators (Zoetis, Merck Animal Health, Boehringer Ingelheim) alongside high-growth regional innovators (including HIPRA, Hester Biosciences, and Vaxxinova) expanding specialized regional capacity.